Blood Purification Systems

Clinical trials for Blood Purification Systems (BPS) present unique challenges due to their critical role in treating life-threatening conditions such as acute kidney injury (AKI), sepsis, and chronic kidney disease (CKD). These trials must rigorously assess safety, efficacy, and biocompatibility while ensuring compliance with stringent regulatory standards. The typical clinical development phases include:

Feasibility & First-in-Human Studies

Small-scale trials evaluate initial safety, tolerability, and technical performance in controlled settings.
Key considerations: Patient selection (e.g., critically ill vs. stable CKD patients), anticoagulation management, and device interaction monitoring.

Pivotal Clinical Trials

Larger, controlled studies compare the BPS against standard dialysis or alternative therapies.
Primary endpoints may include:
Efficacy: Solute clearance (e.g., urea, creatinine), cytokine removal (for sepsis devices)
Safety: Hemolysis risk, clotting events, infection rates
Challenges:
Patient heterogeneity (AKI vs. CKD vs. sepsis populations)
Need for real-time monitoring (e.g., blood flow rates, filter integrity)

Post-Market Clinical Follow-Up (PMCF) & Real-World Studies

Long-term safety and performance monitoring in dialysis centers and ICUs.
Critical for high-risk devices (e.g., wearable artificial kidneys, novel hemoperfusion systems).
Regulatory Considerations:
FDA (PMA/510(k)), EU MDR (Class IIb/III), and ISO 13958/23500 compliance
Biocompatibility testing (ISO 10993) and hemocompatibility (ASTM F756)

End-to-End Clinical Trial Services

As a STEMart brand, Meditronics delivers full-service clinical trial management for BPS, ensuring regulatory success and rapid market entry. Our services include:

Protocol Design & Regulatory Strategy

Customized study designs for hemodialysis, hemofiltration, plasma exchange, and sorbent-based systems
Endpoint selection aligned with FDA/CDRH, EMA, and ISO standards
Statistical planning for non-inferiority/superiority trials

Ethics & Regulatory Submissions

IRB/EC approvals and preparation of IDE (Investigational Device Exemption), CE-MDR Technical Documentation
Local regulatory navigation (e.g., China NMPA, Japan PMDA)

Site Selection & Investigator Training

Global network of nephrology & critical care centers (dialysis clinics, ICUs)
Investigator training on device operation, adverse event reporting, and protocol adherence

Patient Recruitment & Retention

Stratified enrollment for AKI, CKD, sepsis, and poisoning cases
EHR-based screening and patient engagement programs to reduce dropouts

Clinical Monitoring & Data Management

On-site & remote monitoring for treatment adherence and data integrity
EDC (Electronic Data Capture) & ePRO (electronic Patient-Reported Outcomes) integration
Real-time SAE (Serious Adverse Event) tracking

Post-Market Surveillance & Long-Term Follow-Up

PMCF studies for durability and rare adverse events
Registries & real-world evidence (RWE) generation

Protocol Design

Disease-specific frameworks: Tailored protocols for asthma (FEV₁ improvement), sleep apnea (AHI reduction), or ARDS (lung compliance).
Adaptive designs: Adjust enrollment criteria based on interim analyses (e.g., expanding to pediatric cohorts).

Ethics & Regulatory Strategy

Pre-submission meetings with FDA/CDRH or EMA/NB to align on ISO 80601-2-12 (ventilators) or ISO 17510 (sleep apnea devices).
Ethics committee training to address unique consent challenges (e.g., intubated patients in ICU trials).

Trial Site Selection

Tier-1 pulmonary centers with accredited sleep labs or ICUs for ventilator studies.
Home-based trial options for chronic devices (e.g., telemedicine visits for CPAP adherence tracking).

Patient Recruitment

Strict inclusion criteria: Confirm diagnoses via polysomnography (sleep apnea) or spirometry (COPD).
Over-enrollment buffers: Account for high dropout rates in long-term studies (e.g., 6-month CPAP trials).

Clinical Monitoring & Data Management

Real-time respiratory data integration: SpO₂, EtCO₂, and tidal volume metrics synced to EDC systems.
Centralized adjudication: Pulmonologists review adverse events (e.g., auto-PEEP incidents in ventilator trials).

Post-Operative Follow-Up

Extended monitoring: 30–90 days for acute devices (e.g., post-ventilator weaning complications).
PROs & QoL surveys: CAT scores for COPD devices or Epworth Sleepiness Scale for CPAPs.

Blood Purification System Categories We Serve

Meditronics facilitates clinical trials for a wide range of BPS, including:

Conventional Hemodialysis Machines (In-center & portable systems)
Continuous Renal Replacement Therapy (CRRT) Devices (For ICU patients)
Hemoperfusion & Cytokine Adsorption Systems (Sepsis, poisoning)
Wearable & Implantable Artificial Kidneys (Next-gen dialysis solutions)
Plasmapheresis & Albumin Dialysis Systems (Liver failure, autoimmune diseases)

Why Partner with Meditronics for Blood Purification System Trials?

Meditronics stands out as a trusted CRO partner due to:

1. Specialized Nephrology & Critical Care Expertise: Deep understanding of dialysis protocols, anticoagulation management, and ICU trial logistics

2. Global Regulatory Master: Rich experience in FDA (PMA/De Novo), EU MDR, and Asia-Pacific submissions

3. Efficient Trial Execution: Fast site activation, adaptive trial designs, and AI-driven patient matching

4. End-to-End Support: From preclinical hemocompatibility testing to post-market surveillance, we ensure seamless trial progression

5. Compliance & Quality Assurance: ISO 13485-certified processes, GCP/ISO 14155 compliance, risk-based monitoring

By partnering with Meditronics, BPS manufacturers gain a strategic ally that delivers high-quality, compliant, and efficient clinical trials, accelerating regulatory approvals and patient access.

Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Need More Information or Request A Quotation?

Send us a request